American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

RSS icon
Michael J. Reardon, MD, the Allison Family Distinguished Chair in Cardiovascular Research and a professor of medicine at the DeBakey Heart and Vascular Center, Houston Methodist Hospital, explains the late-breaking five-year results of the Evolut Low-Risk Trial presented at the American College of Cardiology (ACC) 2025 meeting. The data show positive results for the Evolut transcatheter aortic valve replacement (TAVR) system vs. surgical aortic valve replacement (SAVR).

Self-expanding TAVR valves deliver outcomes and durability comparable to surgery after 5 years

Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways. 

Society of Cardiovascular Angiography and Interventions (SCAI) President James B. Hermiller, Jr., MD, director of the transcatheter structural heart program at Ascension St. Vincent Heart Center in Indianapolis, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons that cause orthopedic injury.

SCAI pushes for better radiation protection in cath labs

Society of Cardiovascular Angiography and Interventions President James Hermiller, Jr., MD, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons.

Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, explains what he sees as the top recent trials impacting acute coronary syndrome care (ACS).

Tracking major trends and clinical research in acute coronary syndrome care

Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.

Gudrun Feuchtner, MD, MBA, HCM, assistant professor, cardiovascular imaging, Medical University Innsbruck, Department Radiology, explains how artificial intelligence-based quantitative computed tomography (AI QCT) coronary plaque features are better able to predict risk in women, according the the results of the late-breaking CONFIRM2 study at ACC 2025.

AI-based coronary plaque evaluations highlight elevated heart risks in women

“This is the perfect technique to identify high-risk patients who would benefit from intensive therapies,” imaging specialist Gudrun Feuchtner, MD, told Cardiovascular Business.

FIRE1 Norm inferior vena cava (IVC) heart failure sensor

Implantable IVC sensor shows early potential to guide heart failure management

The goal is to measure changes in a patient’s IVC area and collapsibility, which can help anticipate when heart failure events might occur. This first-in-human study included data from the first 50 patients to receive the device. 

Video of Deepak Bhatt explaining the benefits of bentracimab in the late-breaking Phase 3 REVERSE-IT trial.

New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'

Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."

SCAI President James B. Hermiller, Jr., MD, director of the transcatheter structural heart program at Ascension St. Vincent Heart Center, Indianapolis, outlined the organization’s key policy priorities for the year. Among them: physician payment reform, peer review overhaul, medical education debt relief, the elimination of non-compete clauses, and physician mental health protections.

Reimbursements, non-compete clauses and more: SCAI focused on key policies in interventional cardiology

SCAI President James B. Hermiller, Jr., MD, detailed the group's key policy concerns in 2025 and beyond in a new video interview. 

Raj Makkar, MD, director, interventional cardiology, director, Interventional Cardiology Research Program and professor of medicine, Smidt Heart Institute, Cedars-Sinai Hospital, presented the late-breaking Align-AR clinical trial at ACC 2025 on the first 500 patients treated for aortic regurgitation using the Jena Valve transcatheter aortic valve replacement (TAVR) device.

First 500 patients in Align-AR trial using TAVR for pure aortic regurgitation show strong outcomes

Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.

Displaying 41 - 48 of 381
Design by Adaptive Theme